We also showed a putative broad spectrum of antiproliferative activity on a panel of tumor cell lines harboring different gene mutations: K-Ras mutations (H460), EGFR and Her2 amplification (A431 and BT474, respectively), N-Ras mutation (HT1080), PTEN loss (A2780), FLT3 mutation (MV4;11) and c-met amplification (GTL-16). The gene discussed is KRAS; the disease is neoplasm.